Which Types of Transdermal Patches Are Suitable for Continuous Wet-Coating Lines?
Share
Before committing to a transdermal patch production platform, manufacturers face a question that is more consequential than it first appears: does your formulation actually suit continuous wet-coating and drying? The answer determines whether you are specifying the right machine — or investing in a process that is fundamentally misaligned with your product design.
Huanghai's MJ150 pharmaceutical film coating platform is built around continuous wet-coating combined with a patented hot-air drying tunnel (CN201668734U). This architecture is well-suited to several major TDDS formulation categories, and less suited to others. This article explains the distinction plainly, so procurement and R&D teams can make an informed process-formulation match before equipment conversations begin.
What "Continuous Wet-Coating + Drying" Actually Means
The process logic of a wet-coating line follows a simple sequence:
- Formulation preparation: The drug-containing matrix is prepared as a fluid — a solution, suspension, or gel — at or near room temperature
- Web coating: The fluid is applied onto a moving substrate (typically a release liner) via a coating head, at controlled thickness
- Drying tunnel: The coated web passes through a temperature-controlled drying zone where solvent or water is removed, leaving a dry, cohesive drug-containing layer
- Lamination and conversion: A backing liner is laminated onto the dried drug layer; the composite web is then slit and converted into individual patch units
The enabling condition for this process is that the formulation must be coatable as a fluid at the coating stage — meaning it needs to flow, spread, and wet the substrate at controlled viscosity. After the drying step, it should form a dimensionally stable, uniform dry film.
This is a fundamentally different mechanism from hot-melt processing, where the adhesive is melted by heat, applied in a molten state, and solidified on cooling — with no solvent or water to remove.
Formulation Systems Well-Suited to Wet-Coating Lines
1. Solvent-Based Matrix Systems
Solvent-based formulations are among the most commonly used in pharmaceutical TDDS manufacturing. In these systems, the drug and adhesive polymer (typically an acrylate or polyisobutylene-based PSA) are dissolved or dispersed in an organic solvent. The resulting solution is coated onto the release liner, and the solvent is removed by the drying tunnel.
Why this fits wet-coating: - Solvent-based systems are inherently fluid and coatable at room temperature - Solvent removal is precisely managed by the drying tunnel's temperature profile and airflow - Drug-polymer blending is achieved in the solution phase, enabling excellent API distribution uniformity
Process considerations: - Solvent management (containment, recovery, safety) must be addressed in facility design - API must be soluble or uniformly dispersable in the chosen solvent system - Residual solvent specifications apply and are controlled via drying parameters
Huanghai's MJ150 drying tunnel maintains progressive temperature profiling — transitioning from higher to milder temperatures along the tunnel length. This design is particularly important for solvent-based TDDS: too aggressive drying can cause surface skinning before the interior is dry, trapping residual solvent and producing non-uniform API distribution.
2. Water-Based (Aqueous) Matrix Systems
Aqueous formulations — where the drug and polymer are dissolved or dispersed in water rather than organic solvent — are increasingly favored in newer TDDS development, particularly where regulatory and environmental pressures on organic solvents are significant.
Why this fits wet-coating: - Water-based systems are fluid and can be coated onto release liners in the same manner as solvent-based systems - The drying tunnel removes water, leaving a dry, cohesive layer - Aqueous systems can support both matrix-type and certain reservoir-type architectures
Process considerations: - Water has a higher heat of vaporization than most organic solvents, so drying tunnel parameters (temperature, airflow, dwell time) require careful calibration - Aqueous systems may require surfactants or co-solvents to achieve adequate API solubility - Some water-soluble polymers may require specific humidity control post-drying
The hot-air circulation design of Huanghai's tunnel system supports the higher energy input required for aqueous drying while avoiding surface overheating — a common failure mode with plate-based competitors that apply heat from top and bottom surfaces rather than through controlled airflow.
3. Coatable Hydrogel and Gel-Based Systems
Certain hydrogel formulations — including aqueous polymer gels (e.g., carbomer, hydroxypropyl cellulose, polyvinyl alcohol-based systems) — can be coated onto substrates if the gel is engineered to have appropriate flow properties at the coating stage.
Why this may fit wet-coating (depending on formulation): - Gel-based systems can be coated as viscous fluids using appropriate coating heads (e.g., slot-die or comma-bar configurations) - After coating, water or solvent evaporates from the gel phase, leaving a cohesive drug-containing layer - Hydrogel-based transdermal patches are explicitly listed as an application for the Huanghai MJ150 drying tunnel (patent CN201668734U)
Process considerations: - Gel viscosity must be within a range compatible with the coating head geometry — very high-viscosity gels may require specialized application equipment - Drying temperature must be controlled to preserve gel matrix integrity and prevent over-drying or cracking - Feasibility depends on specific formulation rheology; R&D validation is typically required before process lock
This category should be approached as "may be feasible depending on formulation characteristics" rather than universally compatible. Huanghai's team can evaluate specific gel formulation parameters when considering process design.
Formulation Systems That Are Not the Primary Fit
Hot-Melt Adhesive (HMA) Patch Systems
Hot-melt adhesive systems are the primary manufacturing method for many traditional consumer patches — including many OTC analgesic patches, sports patches, and wound care products. In HMA processing, the adhesive is melted to a molten state (typically at elevated temperatures), applied to the substrate in its liquid form, and then cooled to solidify.
Why HMA does not fit wet-coating lines: - No solvent or water is involved — there is nothing for the drying tunnel to remove - The coating must be applied at elevated temperature, requiring a fundamentally different coating head and substrate handling system - Wet-coating line infrastructure (solvent containment, tunnel airflow) is not required and not applicable
HMA systems are widely used for traditional plasters, hydrocolloid dressings, and some OTC analgesic patches. They are not the primary application target for pharmaceutical-grade continuous wet-coating lines such as the MJ150.
This is not a criticism of HMA as a technology — it is simply a process-compatibility distinction. If your product design requires HMA processing, a wet-coating line is not the right equipment category to evaluate.
Decision Framework: Matching Formulation to Process
Use the following questions to evaluate wet-coating line compatibility before engaging equipment suppliers:
| Question | If Yes → | If No → |
|---|---|---|
| Is the formulation a fluid (solution, suspension, or gel) at the coating stage? | Likely compatible with wet-coating | Consider whether HMA or alternative process is needed |
| Does the formulation contain a solvent or water that must be removed after coating? | Wet-coating + drying is the relevant process | HMA or lamination may be more appropriate |
| Is API uniformity a critical quality attribute subject to pharmacopoeial specifications? | Pharmaceutical-grade wet-coating platform needed | Simpler systems may suffice |
| Is GMP cleanroom production required? | Pharmaceutical-grade platform needed | Consumer-grade equipment may apply |
| Best fit for | Solvent-based, aqueous, and certain gel-based pharmaceutical TDDS | Traditional hot-melt adhesive patch systems |
Frequently Asked Questions
Q: Can the same wet-coating line produce both ODF (oral dissolving film) and transdermal patches? A: The core process equipment is compatible — both ODF and pharmaceutical TDDS use fluid coating followed by a drying step. However, switching between ODF and TDDS production involves format-specific tooling and changeover work that requires Huanghai engineering support. In practice, most customers operate separate dedicated machines for ODF and TDDS production. If dual-format capability on a single platform is a priority for your project, contact Huanghai to evaluate the configuration requirements for your specific products.
Q: How does the drying tunnel design affect TDDS product quality? A: Critically. The drying tunnel must remove solvent or water uniformly across the entire width of the coated web, without overheating surface layers or leaving residual solvent gradients that produce API distribution non-uniformity. Huanghai's patented hot-air tunnel (CN201668734U) uses progressive temperature profiling — transitioning from higher temperatures at the entry zone to milder temperatures at the exit — combined with uniform airflow across the film surface. This design avoids the "hot edge" effect and surface hardening that commonly occur with plate-based heating systems, and provides 20–30% higher drying efficiency compared to conventional oven designs.
Q: Is a wet-coating line suitable for high-viscosity gel formulations? A: It depends on the specific formulation viscosity and the coating head configuration. Slot-die or comma-bar coating heads can handle a range of viscosities, but very high-viscosity gels (e.g., thick carbomer gels) may require specialized application equipment or formulation adjustment to achieve consistent coating weight. Huanghai recommends providing formulation rheology data early in the evaluation process so that process compatibility can be assessed before equipment specification.
Q: What throughput can be expected from a pharmaceutical TDDS wet-coating line? A: The MJ150 platform is rated at 20,000 films/hour for ODF production, with an upgrade plan available to reach up to 40,000 films/hour for high-volume commercial lines. Actual throughput for TDDS applications depends on patch dimensions, drying requirements (solvent type, loading level, target residual), and the complexity of post-coating lamination steps. For R&D and pilot-scale work, the MJ150-L operates at 8,000–10,000 films/hour and uses the same process logic as the commercial platform, allowing direct process transfer at scale-up.
Q: What facility requirements does a solvent-based TDDS wet-coating line need? A: Solvent-based systems require dedicated solvent storage and handling infrastructure, solvent vapor containment, and typically solvent recovery or abatement systems — all of which are facility design considerations addressed during plant layout planning. Huanghai can provide guidance on equipment boundary conditions (solvent exposure zones, ventilation interface points) during the project scoping phase.
Conclusion
Continuous wet-coating lines are especially well-suited to pharmaceutical TDDS formulations based on solvent-based systems, aqueous systems, and certain coatable gel or hydrogel architectures. They are not designed for traditional hot-melt adhesive patch systems, which operate on a different processing principle entirely.
For teams at the formulation design or early equipment evaluation stage, aligning process type to formulation type early — before machine specifications are written — avoids costly mismatches downstream.
Contact Huanghai to discuss your formulation type, target throughput, and regulatory requirements. Our team works with clients from pilot-scale validation through commercial line configuration for pharmaceutical-grade TDDS production.